Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Subjects

Subjects :

Adenine analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Alleles
Biomarkers, Tumor metabolism
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Class I Phosphatidylinositol 3-Kinases antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases genetics
Class I Phosphatidylinositol 3-Kinases metabolism
Gene Expression
Gene Frequency
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Molecular Targeted Therapy
Piperidines
Prognosis
Protein-Tyrosine Kinases antagonists & inhibitors
Protein-Tyrosine Kinases genetics
Protein-Tyrosine Kinases metabolism
Purines therapeutic use
Pyrazoles therapeutic use
Pyrimidines therapeutic use
Quinazolinones therapeutic use
Sulfonamides therapeutic use
Tumor Suppressor Protein p53 deficiency
Antineoplastic Agents therapeutic use
Biomarkers, Tumor genetics
Leukemia, Lymphocytic, Chronic, B-Cell diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Tumor Suppressor Protein p53 genetics

Details

Language :

English

ISSN :

1592-8721

Volume :

101

Issue :

3

Database :

MEDLINE

Journal :

Haematologica

Publication Type :

Report

Accession number :

26928246

Full Text :

https://doi.org/10.3324/haematol.2015.139246